.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Randomized evidence has shown that immune-checkpoint inhibition can produce substantial benefit in advanced or recurrent endometrial cancer, particularly in tumors with mismatch repair deficiency or microsatellite instability. The KEYNOTE-158 and related studies established durable responses to pembrolizumab in biomarker-selected populations, while later randomized trials expanded the role of immunotherapy in first-line treatment. For clinicians, tumor molecular classification is therefore increasingly central to management. Testing for mismatch repair proteins or microsatellite instability can identify patients most likely to benefit from immune checkpoint blockade and can also flag potential hereditary Lynch syndrome. Treatment requires monitoring for immune-related adverse events affecting the thyroid, liver, bowel, lung and other organs. The practical implication is that gynecologic oncology is moving toward integrated histologic, molecular and clinical decision-making.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Randomized evidence has shown that immune-checkpoint inhibition can produce substantial benefit in advanced or recurrent endometrial cancer, particularly in tumors with mismatch repair deficiency or microsatellite instability. The KEYNOTE-158 and related studies established durable responses to pembrolizumab in biomarker-selected populations, while later randomized trials expanded the role of immunotherapy in first-line treatment. For clinicians, tumor molecular classification is therefore increasingly central to management. Testing for mismatch repair proteins or microsatellite instability can identify patients most likely to benefit from immune checkpoint blockade and can also flag potential hereditary Lynch syndrome. Treatment requires monitoring for immune-related adverse events affecting the thyroid, liver, bowel, lung and other organs. The practical implication is that gynecologic oncology is moving toward integrated histologic, molecular and clinical decision-making.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
Last week
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
